The FDA has granted accelerated approval to a new treatment strategy for certain people with advanced breast cancer—one that can begin after a resistance mutation appears in a blood test but before imaging shows that the cancer has progressed. Etcamah, also known as camizestrant, was approved September 4 in combination with one of three CDK4/6 inhibitors: abemaciclib, palbociclib or ribociclib. The treatment is specifically for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer who develop an ESR1 mutation while being treated with an aromatase inhibitor and CDK4/6 inhibitor.
